{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:17:46Z","timestamp":1783106266998,"version":"3.54.6"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103552"],"award-info":[{"award-number":["82103552"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802598"],"award-info":[{"award-number":["81802598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Maternal and Child Health Research","award":["F202165"],"award-info":[{"award-number":["F202165"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent or metastatic cervical cancer, but responses are heterogeneous and biomarkers beyond programmed death-ligand 1 (PD-L1) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Targeted sequencing of 437 cancer-related genes was performed in 42 patients receiving ICI-based therapy. Genomic correlates of progression-free survival (PFS) were evaluated, and an exploratory prognostic model was developed using least absolute shrinkage and selection operator regression and multivariable Cox regression. The Cancer Genome Atlas (TCGA) cohort was used for transcriptomic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 42 patients, with a median age of 51\u2009years; 85.7% were human papillomavirus-positive, 90.5% had squamous cell carcinoma, and 54.8% had a programmed death-ligand 1 combined positive score (PD-L1 CPS) \u22655. Frequent alterations included PIK3CA (57.1%), FBXW7 (21.4%), TERT (21.4%), BAP1 (19.0%), and EP300 (16.7%). Tumor mutational burden-associated mutations in PIK3CA, EP300, CREBBP, and TERT were associated with prolonged PFS (P\u2009&amp;lt;\u2009.001), whereas PD-L1\u2013associated mutations showed numerically longer PFS (P\u2009=\u2009.170). EP300 (P\u2009=\u2009.007), PIK3CA (P\u2009&amp;lt;\u2009.01), and homologous recombination repair pathway alterations (P\u2009=\u2009.016) were associated with favorable PFS, whereas KEAP1 (P\u2009&amp;lt;\u2009.01) and TP53 (P\u2009=\u2009.010) mutations were associated with shorter PFS. A five-feature genomic model stratified patients into high- and low-risk groups (P\u2009&amp;lt;\u2009.001, 1-year AUC\u2009=\u2009.889). In the exploratory cohort, high-risk patients showed numerically shorter PFS (P\u2009=\u2009.060). In TCGA samples, high-risk tumors showed enrichment of angiogenesis, epithelial-mesenchymal transition, hypoxia, inflammatory response, and tumor necrosis factor-\u03b1\/nuclear factor-\u03baB signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Specific genomic alterations may help stratify immunotherapy outcomes in recurrent or metastatic cervical cancer. The proposed genomic risk model remains exploratory and requires validation in larger, independent cervical cancer cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag236","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:23:45Z","timestamp":1782127425000},"source":"Crossref","is-referenced-by-count":0,"title":["Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Lingling","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Medical Image Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University , Nanjing 210000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University , Nanjing 210000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Liu","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Yin","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Geneseeq Research Institute, Nanjing Geneseeq Technology Inc , Nanjing 210032,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University , Nanjing 210000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4040-3977","authenticated-orcid":false,"given":"Yaqin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University , Nanjing 210000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026070314403313600_oyag236-B1","volume-title":"Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem","author":"Organization WH","year":"2020"},{"key":"2026070314403313600_oyag236-B2","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070314403313600_oyag236-B3","doi-asserted-by":"crossref","first-page":"15022","DOI":"10.3390\/ijms232315022","article-title":"Hpv-negative adenocarcinomas of the uterine cervix: from molecular characterization to clinical implications","volume":"23","author":"Giannella","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026070314403313600_oyag236-B4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5483\/BMBRep.2022.55.9.042","article-title":"Untold story of human cervical cancers: HPV-negative cervical cancer","volume":"55","author":"Lee","year":"2022","journal-title":"BMB Rep"},{"key":"2026070314403313600_oyag236-B5","doi-asserted-by":"crossref","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (hpv) vaccinology","volume":"15","author":"Williamson","year":"2023","journal-title":"Viruses"},{"key":"2026070314403313600_oyag236-B6","article-title":"Vascular endothelial growth factor (vegf) targeting therapy for persistent, recurrent, or metastatic cervical cancer","volume":"3","author":"Li","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070314403313600_oyag236-B7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"7Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"2026070314403313600_oyag236-B8","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0090-8258(21)00696-X","article-title":"Pembrolizumab treatment of advanced cervical cancer: updated results from the phase ii keynote-158 study","volume":"162","author":"Chung","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026070314403313600_oyag236-B9","doi-asserted-by":"crossref","first-page":"115146","DOI":"10.1016\/j.ejca.2024.115146","article-title":"Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase iii empower-cervical 1\/gog-3016\/engot-cx9 trial","volume":"216","author":"Oaknin","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026070314403313600_oyag236-B10","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070314403313600_oyag236-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026070314403313600_oyag236-B12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S","year":"2017","journal-title":"Nature"},{"key":"2026070314403313600_oyag236-B13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2020.10.004","article-title":"Apobec: a molecular driver in cervical cancer pathogenesis","volume":"496","author":"Revathidevi","year":"2021","journal-title":"Cancer Lett"},{"key":"2026070314403313600_oyag236-B14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5582\/bst.2017.01103","article-title":"Apobec-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis","volume":"11","author":"Chen","year":"2017","journal-title":"Biosci Trends"},{"key":"2026070314403313600_oyag236-B15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"key":"2026070314403313600_oyag236-B16","doi-asserted-by":"crossref","first-page":"1498053","DOI":"10.1155\/2022\/1498053","article-title":"Somatic alteration characteristics of early-onset gastric cancer","volume":"2022","author":"Zhou","year":"2022","journal-title":"J Oncol"},{"key":"2026070314403313600_oyag236-B17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 keynote-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070314403313600_oyag236-B18","doi-asserted-by":"crossref","first-page":"608742","DOI":"10.3389\/fgene.2021.608742","article-title":"Genomic profiling reveals the molecular landscape of gastrointestinal tract cancers in Chinese patients","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Genet"},{"key":"2026070314403313600_oyag236-B19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"key":"2026070314403313600_oyag236-B20","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","article-title":"Gsea-p: a desktop application for gene set enrichment analysis","volume":"23","author":"Subramanian","year":"2007","journal-title":"Bioinformatics"},{"key":"2026070314403313600_oyag236-B21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2026070314403313600_oyag236-B22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"Xcell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2026070314403313600_oyag236-B23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002223","article-title":"Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the clap trial","volume":"9","author":"Huang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070314403313600_oyag236-B24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"2026070314403313600_oyag236-B25","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1002\/cam4.3376","article-title":"Tert mutations correlate with higher tmb value and unique tumor microenvironment and may be a potential biomarker for anti-ctla4 treatment","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"key":"2026070314403313600_oyag236-B26","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1038\/s41598-020-66329-7","article-title":"In silico analysis reveals ep300 as a pancancer inhibitor of anti-tumor immune response via metabolic modulation","volume":"10","author":"Krupar","year":"2020","journal-title":"Sci Rep"},{"key":"2026070314403313600_oyag236-B27","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.18632\/aging.102728","article-title":"Ep300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients","volume":"12","author":"Zhu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2026070314403313600_oyag236-B28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/2159-8290.CD-19-1416","article-title":"Inactivation of fbxw7 impairs dsrna sensing and confers resistance to pd-1 blockade","volume":"10","author":"Gstalder","year":"2020","journal-title":"Cancer Discov"},{"key":"2026070314403313600_oyag236-B29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fimmu.2019.01113","article-title":"Association of lrp1b mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2026070314403313600_oyag236-B30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/JHC.S348785","article-title":"Lrp1b is a potential biomarker for tumor immunogenicity and prognosis of hcc patients receiving ici treatment","volume":"9","author":"Cheng","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"2026070314403313600_oyag236-B31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003773","article-title":"Genomic profiles and their associations with tmb, pd-l1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers","volume":"9","author":"Hu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026070314403313600_oyag236-B32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/pathogens14070668","article-title":"Molecular features of hpv-independent cervical cancers","volume":"14","author":"Giannella","year":"2025","journal-title":"Pathogens"},{"key":"2026070314403313600_oyag236-B33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12885-023-10775-9","article-title":"Evaluating the prognostic significance of p53 and tp53 mutations in hpv-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"2026070314403313600_oyag236-B34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"Stk11\/lkb1 mutations and pd-1 inhibitor resistance in kras-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"2026070314403313600_oyag236-B35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12964-024-01586-x","article-title":"Role of sting in the treatment of non-small cell lung cancer","volume":"22","author":"Tang","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2026070314403313600_oyag236-B36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12920-019-0579-3","article-title":"Integrative genomic analyses of apobec-mutational signature, expression and germline deletion of apobec3 genes, and immunogenicity in multiple cancer types","volume":"12","author":"Chen","year":"2019","journal-title":"BMC Med Genomics"},{"key":"2026070314403313600_oyag236-B37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to pd-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070314403313600_oyag236-B38","doi-asserted-by":"crossref","first-page":"602328","DOI":"10.3389\/fmolb.2020.602328","article-title":"Prognostic biomarker tp53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma","volume":"7","author":"Lin","year":"2020","journal-title":"Front Mol Biosci"},{"key":"2026070314403313600_oyag236-B39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jtho.2021.08.010","article-title":"Keap1 and tp53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy","volume":"16","author":"Scalera","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026070314403313600_oyag236-B40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implications of keap1-nfe2l2 mutations in nsclc","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026070314403313600_oyag236-B41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41698-024-00672-0","article-title":"The intersection of homologous recombination (hr) and mismatch repair (mmr) pathways in DNA repair-defective tumors","volume":"8","author":"Incorvaia","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026070314403313600_oyag236-B42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ol.2024.14700","article-title":"Pi3k\/akt\/mtor and pd\u20111\/ctla\u20114\/cd28 pathways as key targets of cancer immunotherapy (review)","volume":"28","author":"Wang","year":"2024","journal-title":"Oncol Lett"},{"key":"2026070314403313600_oyag236-B43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026070314403313600_oyag236-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","article-title":"Tgf-beta, emt, and resistance to anti-cancer treatment","volume":"97","author":"Wang","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"2026070314403313600_oyag236-B45","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined pd-l1\/tgfbeta blockade allows expansion and differentiation of stem cell-like cd8 t cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag236\/68580678\/oyag236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag236\/68580678\/oyag236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag236\/68580678\/oyag236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:40:45Z","timestamp":1783104045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag236\/8713564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag236","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,6]]},"article-number":"oyag236"}}